Serum omentin-1 presented a similar diagnostic performance to that of tumor biomarker CA15-3 in BC with a poorer discriminative ability in postmenopausal women with obesity; however, it may reflect advanced disease stage (II and III), increased number of infiltrated lymph nodes, and negative hormonal receptor status. This evidence concerns the gene NR4A1 and breast cancer.